Raymie McFarland

TL;DR: This retrospective observational study of laboratory-confirmed COVID-19 adults evaluated glycemic and clinical outcomes in patients with and without diabetes and/or acutely uncontrolled hyperglycemia hospitalized March 1 to April 6, 2020, finding that patients with diabetes and or uncontrolled hyper glycemia had a longer LOS and markedly higher mortality than patients without diabetes.

TL;DR: Both hyperglycemia and hypoglycemia were associated with poor outcomes in patients with COVID-19, and admission glucose was a strong predictor of death among patients directly admitted to the ICU and non-ICU patients.

TL;DR: The GM algorithm in DKA treatment resulted in lower rates of hypoglycemia and faster DKA resolution over standard paper-based algorithms and prospective randomized clinical trials are warranted.

TL;DR: Patients using eGMS in the DGM group achieved improved glycemic control with lower incidence of hypoglycemia compared to both BGM and AGM management with standard treatment, suggesting that an eG MS can safely maintain glucose control with less hypoglyCEmia than basal bolus treatment managed by a provider.

TL;DR: A retrospective review to compare BG control, time in target BG range, and the rate of hypoglycemia when critically ill patients were managed with an insulin infusion guided by paper-based protocol (PBP) versus eGMS found an eG MS has the potential to address many of the unmet needs of an optimal glycemic control strategy, minimizing hypoglyCEmia, and glycemic variability in a heterogeneous critically ill population.